2 Introduction 9 2.1 Disease Introduction 9 2.2 Symptoms 10 2.3 Etiology 10 2.4 Pathophysiology 10 2.5 Diagnosis 11 2.5.1 Physical Examination 11 2.5.2 Blood Tests 11 2.5.3 1987 Rheumatoid Arthritis Classification 12 2.5.4 The 2010 ACR-EULAR Classification Criteria for Rheumatoid Arthritis 12 2.6 Epidemiology 13 2.7 Co-morbidities and Complications 13 2.8 Disease Progression 14 2.9 Pharmacotherapy Algorithm 14 2.10 Treatment Options 16
View summary of this report @ http:// www. radiantinsights. com / research / rheumatoidarthritis-market-to-2020-a-crowded-market-characterized-by-modest-growth
2.10.1 Pharmacological 16 2.10.2 Methotrexate 16 2.10.3 Plaquenil( hydroxychloroquine) 16 2.10.4 Arava( leflunomide) 16 2.10.5 Azulfidine, Salazopyrin( sulfasalazine) 17 2.10.6 Neoral( cyclosporine) 17
2.10.7 Prograf( tacrolimus) 17
2.10.8 Xeljanz( tofacitinib) 17 2.11 Other Non-biologics 17
Follow Us: